These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 37038675)
1. GPR18 and GPR55-related Ligands Serving as Antagonists or Agonists: Current Situation, Challenges and Perspectives. Zhang L; Fang Y; Hang S; Wu W; Sheng R; Guo R Med Chem; 2023; 19(9):838-847. PubMed ID: 37038675 [TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. Schoeder CT; Kaleta M; Mahardhika AB; Olejarz-Maciej A; Łażewska D; Kieć-Kononowicz K; Müller CE Eur J Med Chem; 2018 Jul; 155():381-397. PubMed ID: 29902723 [TBL] [Abstract][Full Text] [Related]
3. A GPR18-based signalling system regulates IOP in murine eye. Caldwell MD; Hu SS; Viswanathan S; Bradshaw H; Kelly ME; Straiker A Br J Pharmacol; 2013 Jun; 169(4):834-43. PubMed ID: 23461720 [TBL] [Abstract][Full Text] [Related]
7. Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18. Neumann A; Engel V; Mahardhika AB; Schoeder CT; Namasivayam V; Kieć-Kononowicz K; Müller CE Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365486 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18. Schoeder CT; Mahardhika AB; Drabczyńska A; Kieć-Kononowicz K; Müller CE ACS Med Chem Lett; 2020 Oct; 11(10):2024-2031. PubMed ID: 33062188 [TBL] [Abstract][Full Text] [Related]
9. Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. Guerrero-Alba R; Barragán-Iglesias P; González-Hernández A; Valdez-Moráles EE; Granados-Soto V; Condés-Lara M; Rodríguez MG; Marichal-Cancino BA Front Pharmacol; 2018; 9():1496. PubMed ID: 30670965 [No Abstract] [Full Text] [Related]
10. Central GPR55 may prevent nicotine reinforcing actions: a preliminary study. Díaz-Barba A; Calvillo-Robledo A; Vázquez-León P; Gallegos-Vieyra E; Quintanar JL; Marichal-Cancino BA Acta Neurobiol Exp (Wars); 2022; 82(3):304-314. PubMed ID: 36214713 [TBL] [Abstract][Full Text] [Related]
11. Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. Ramírez-Orozco RE; García-Ruiz R; Morales P; Villalón CM; Villafán-Bernal JR; Marichal-Cancino BA Curr Neuropharmacol; 2019; 17(10):947-960. PubMed ID: 31146657 [TBL] [Abstract][Full Text] [Related]
12. The Mechanisms of GPR55 Receptor Functional Selectivity during Apoptosis and Proliferation Regulation in Cancer Cells. Akimov MG; Gretskaya NM; Dudina PV; Sherstyanykh GD; Zinchenko GN; Serova OV; Degtyaryova KO; Deyev IE; Bezuglov VV Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982628 [TBL] [Abstract][Full Text] [Related]
13. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Zhao P; Abood ME Life Sci; 2013 Mar; 92(8-9):453-7. PubMed ID: 22820167 [TBL] [Abstract][Full Text] [Related]
14. Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. McHugh D; Page J; Dunn E; Bradshaw HB Br J Pharmacol; 2012 Apr; 165(8):2414-24. PubMed ID: 21595653 [TBL] [Abstract][Full Text] [Related]
15. Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. Rempel V; Volz N; Gläser F; Nieger M; Bräse S; Müller CE J Med Chem; 2013 Jun; 56(11):4798-810. PubMed ID: 23679955 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Sharir H; Abood ME Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715 [TBL] [Abstract][Full Text] [Related]
17. Advances Towards The Discovery of GPR55 Ligands. Morales P; Jagerovic N Curr Med Chem; 2016; 23(20):2087-100. PubMed ID: 27109575 [TBL] [Abstract][Full Text] [Related]
18. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Kotsikorou E; Sharir H; Shore DM; Hurst DP; Lynch DL; Madrigal KE; Heynen-Genel S; Milan LB; Chung TD; Seltzman HH; Bai Y; Caron MG; Barak LS; Croatt MP; Abood ME; Reggio PH Biochemistry; 2013 Dec; 52(52):9456-69. PubMed ID: 24274581 [TBL] [Abstract][Full Text] [Related]
19. GPR55 - a putative "type 3" cannabinoid receptor in inflammation. Yang H; Zhou J; Lehmann C J Basic Clin Physiol Pharmacol; 2016 May; 27(3):297-302. PubMed ID: 26669245 [TBL] [Abstract][Full Text] [Related]